Hematologic adverse events associated with temozolomide

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 107-113

  Villano, J Lee ^a   Letarte, Nathalie ^b   Yu, Janny M ^a   Abdur, Shakir ^a   Bressler, Linda R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Alkylating chemotherapy; Aplastic anemia; Brain tumor; Secondary leukemia; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; AGRANULOCYTOSIS; APLASIA; APLASTIC ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW DEPRESSION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG FATALITY; DRUG INDUCED CANCER; DRUG SAFETY; EPENDYMOMA; FEMALE; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MELANOMA; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; OUTCOMES RESEARCH; PANCYTOPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DATABASES, FACTUAL; HEMATOLOGIC DISEASES; HUMANS; RISK; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856690926     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1679-8     Document Type: Article

References (36)

1. TS Armstrong Y Cao ME Scheurer E Vera-Bolanos R Manning MF Okcu M Bondy R Zhou MR Gilbert 2009 Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors Neuro Oncol 11 825 832 19179423 10.1215/15228517-2008-120 1:CAS:528:DC%2BC3cXotVOrtw%3D%3D
2. S Bailey A Singh R Azadian P Huber M Blum 2010 Prospective data mining of six products in the US FDA adverse event reporting system: disposition of events identified and impact on product safety profiles Drug Saf 33 139 146 20082540 10.2165/11319000-000000000-00000
3. SM Belknap TM Kuzel PR Yarnold N Slimack EA Lyons DW Raisch CL Bennett 2006 Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project Cancer 106 2051 2057 16568459 10.1002/cncr.21808 1:CAS:528:DC%2BD28XkvFGhs7c%3D (Pubitemid 43673222)
4. M Briegert AH Enk B Kaina 2007 Change in expression of MGMT during maturation of human monocytes into dendritic cells DNA Repair (Amst) 6 1255 1263 10.1016/j.dnarep.2007.02.008 1:CAS:528:DC%2BD2sXpt1arurw%3D (Pubitemid 47238680)
5. KR Carson AM Evens EA Richey TM Habermann D Focosi JF Seymour J Laubach SD Bawn LI Gordon JN Winter RR Furman JM Vose AD Zelenetz R Mamtani DW Raisch GW Dorshimer ST Rosen K Muro NR Gottardi-Littell RL Talley O Sartor D Green EO Major CL Bennett 2009 Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project Blood 113 4834 4840 19264918 10.1182/blood-2008-10-186999 1:CAS:528:DC%2BD1MXmslalsbw%3D
6. MC Chamberlain J Raizer 2009 Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia J Neurooncol 93 229 232 19099199 10.1007/s11060-008-9764-5 1:CAS:528:DC%2BD1MXlvFOms74%3D
7. S De Vita S De Matteis L Laurenti P Chiusolo G Reddiconto A Fiorini G Leone S Sica 2005 Secondary Ph+ acute lymphoblastic leukemia after temozolomide Ann Hematol 84 760 762 16044311 10.1007/s00277-005-1093-6 (Pubitemid 41447813)
8. I Dokal T Vulliamy 2008 Inherited aplastic anaemias/bone marrow failure syndromes Blood Rev 22 141 153 18164793 10.1016/j.blre.2007.11.003 1:CAS:528:DC%2BD1cXmsl2qtLo%3D
9. Doyle TJ, Mikkelsen T, Croteau D, Ali H, Anderson J, Beasse R, Rogers L, Rosenblum M, Ryu S (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): report of a phase II trial. J Clin Oncol 23: (abstract # 1546)
10. F Drablos E Feyzi PA Aas CB Vaagbo B Kavli MS Bratlie J Pena-Diaz M Otterlei G Slupphaug HE Krokan 2004 Alkylation damage in DNA and RNA-repair mechanisms and medical significance DNA Repair (Amst) 3 1389 1407 10.1016/j.dnarep.2004.05.004 1:CAS:528:DC%2BD2cXnsleitb4%3D (Pubitemid 39221738)
11. 6- alkylguanine-DNA alkyltransferase Biochem Pharmacol 75 618 626 17996846 10.1016/j.bcp.2007.09.022 1:CAS:528:DC%2BD1cXlvVOhtg%3D%3D
12. F DA 2007 Temozolomide (marketed as Temodar): aplastic anemia Drug Saf Newsl 1 7
13. H Geiger D Schleimer KJ Nattamai SR Dannenmann SM Davies BD Weiss 2006 Mutagenic potential of temozolomide in bone marrow cells in vivo Blood 107 3010 3011 16554488 10.1182/blood-2005-09-3649 1:CAS:528:DC%2BD28XjtlKksLk%3D
14. BJ George JB Eichinger TJ Richard 2009 A rare case of aplastic anemia caused by temozolomide South Med J 102 974 976 19668033 10.1097/SMJ. 0b013e3181b1d2fa
15. DE Gerber SA Grossman M Zeltzman MA Parisi L Kleinberg 2007 The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas Neuro Oncol 9 47 52 17108062 10.1215/15228517-2006-024 1:CAS:528:DC%2BD2sXht1Ojs7g%3D (Pubitemid 46543488)
16. 6- alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU Blood 88 1649 1655 8781420 1:CAS:528:DyaK28Xlt1Kktbo%3D (Pubitemid 26307059)
17. BJ Glassner G Weeda JM Allan JL Broekhof NH Carls I Donker BP Engelward RJ Hampson R Hersmus MJ Hickman RB Roth HB Warren MM Wu JH Hoeijmakers LD Samson 1999 DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents Mutagenesis 14 339 347 10375003 10.1093/mutage/14.3.339 1:CAS:528:DyaK1MXjsFShs7w%3D (Pubitemid 29219020)
18. 6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice Carcinogenesis 28 1111 1116 17116724 10.1093/carcin/bgl218 1:CAS:528:DC%2BD2sXlvFGltr4%3D (Pubitemid 47072198)
19. N Hijiya KK Ness RC Ribeiro MM Hudson 2009 Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues Cancer 115 23 35 19072983 10.1002/cncr.23988 1:CAS:528:DC%2BD1MXhsl2ju7s%3D
20. R Jalali P Singh H Menon S Gujral 2007 Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide J Neurooncol 85 105 107 17505778 10.1007/s11060-007-9398-z (Pubitemid 47422663)
21. P Karran J Offman M Bignami 2003 Human mismatch repair, drug-induced DNA damage, and secondary cancer Biochimie 85 1149 1160 14726020 10.1016/j.biochi.2003.10.007 1:CAS:528:DC%2BD2cXjsVyqsg%3D%3D (Pubitemid 38142368)
22. JM McKoy C Angelotta CL Bennett MS Tallman M Wadleigh AM Evens TM Kuzel SM Trifilio DW Raisch J Kell DJ DeAngelo FJ Giles 2007 Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project Leuk Res 31 599 604 16959316 10.1016/j.leukres.2006.07.005 1:CAS:528:DC%2BD2sXkt1aqsb4%3D (Pubitemid 46578145)
23. 6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells Cancer Res 68 6171 6180 18676840 10.1158/0008-5472.CAN-08-0320 1:CAS:528:DC%2BD1cXpt1Squ7w%3D
24. B Morris U Reiss K Kasow A Broniscer 2008 Bone marrow transplantation (BMT) for aplastic anemia secondary to temozolomide therapy in a long-term survivor with glioblastomamultiforme (GBM) Neuro-Oncol 10 396 (abstract CR2)
25. 6-methylguanine-DNA methyltransferase status J Neurooncol 92 227 232 19037596 10.1007/s11060-008-9754-7
26. V Noronha N Berliner KK Ballen J Lacy J Kracher J Baehring JW Henson 2006 Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature Neuro Oncol 8 280 283 16728498 10.1215/15228517-2006-003 (Pubitemid 46542652)
27. J Pedersen-Bjergaard MK Andersen MT Andersen DH Christiansen 2008 Genetics of therapy-related myelodysplasia and acute myeloid leukemia Leukemia 22 240 248 18200041 10.1038/sj.leu.2405078 1:CAS:528:DC%2BD1cXhvVyltb4%3D (Pubitemid 351250527)
28. 6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res. doi: 10.1097/CMR. 0b013e32832ccd58
29. C Seedhouse N Russell 2007 Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia Br J Haematol 137 513 529 17539774 10.1111/j.1365-2141.2007.06613.x 1:CAS:528:DC%2BD2sXot1KqsLw%3D (Pubitemid 46817341)
30. N Singhal S Selva-Nayagam MP Brown 2007 Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature J Neurooncol 85 229 230 17530175 10.1007/s11060-007-9403-6 1:CAS:528:DC%2BD2sXhtl2gs7rK (Pubitemid 47629406)
31. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
32. YW Su MC Chang MF Chiang RK Hsieh 2005 Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma J Neurooncol 71 315 318 15735923 10.1007/s11060-004-2028-0 (Pubitemid 40372963)
33. R Thind RG Torcuator TJ Doyle J Andersen R Loutfi A Haythem S Remer L Schultz T Mikkelsen 2009 The role of demographic and genetic factors in temozolomide-related severe myelotoxicity Neuro Oncol 11 630
34. JL Villano CA Collins EE Manasanch C Ramaprasad K van Besien 2006 Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide Lancet Oncol 7 436 438 16648049 10.1016/S1470-2045(06)70696-9
35. JL Villano TE Seery LR Bressler 2009 Temozolomide in malignant gliomas: current use and future targets Cancer Chemother Pharmacol 64 647 655 19543728 10.1007/s00280-009-1050-5 1:CAS:528:DC%2BD1MXptFCksLw%3D
36. LJ Worrillow AG Smith K Scott M Andersson AJ Ashcroft GM Dores B Glimelius E Holowaty GH Jackson GL Jones CF Lynch G Morgan E Pukkala D Scott HH Storm PR Taylor M Vyberg E Willett LB Travis JM Allan 2008 Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma J Med Genet 45 142 146 17959715 10.1136/jmg.2007.053850 1:CAS:528:DC%2BD1cXks1Wjsro%3D (Pubitemid 351373742)